GSK stock falls 1.18 percent as Berenberg raises its target

Published on 09/22/2026 at 12:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK stock closed at GBX 1,877.50 on September 21, 2026, after a 1.18 percent fall. Berenberg raised its target to GBP 22 from GBP 20.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK plc (GB0009252882) closed at GBX 1,877.50 on the London Stock Exchange on September 21, 2026, down 1.18 percent from the previous session. The move came as Berenberg upgraded GSK from hold to buy and raised its price target from GBP 20 to GBP 22 on September 22, 2026.

Berenberg raises its target

According to Sharecast on September 22, 2026, Berenberg changed its GSK rating from hold to buy and lifted the target from GBP 20 to GBP 22. The broker cited recent business development activity and pipeline momentum, while arguing that the valuation discount had become excessive.

The new target is GBP 2 above the previous target, equivalent to a 10 percent increase. Against the September 21 closing price of GBP 18.775, the GBP 22 target stands GBP 3.225 higher, although the market move itself was negative.

Price falls against London market

The September 21 session produced a clear market comparison. GSK fell 1.18 percent, while the London Stock Exchange benchmark declined 0.19 percent to 8,246.0, leaving GSK 0.99 percentage points behind the index.

The shares traded between GBX 1,852.50 and GBX 1,912.00 during the session, and volume reached about 15.67 million shares. The figures show a wide intraday range of GBX 59.50 around the closing price, with the closing level nearer the session low than the high.

Pipeline remains the central issue

The Berenberg view places business development and the pharmaceutical pipeline above the immediate one-day price reaction. GSK's ViiV Healthcare business also highlighted investment commitments for paediatric and adolescent treatment access in communications referenced on September 21, 2026, adding a specialty-medicines angle to the current backdrop.

For investors, the key contrast is between the broker's longer-term valuation argument and the latest market evidence: the target rose from GBP 20 to GBP 22, but GSK still lost 1.18 percent on September 21 while London equities fell 0.19 percent.

GSK stock closes at GBP 18.775

GSK stock closed at GBP 18.775, or GBX 1,877.50, on the London Stock Exchange on September 21, 2026. Trading volume was about 15.67 million shares, and the next reference point is the GBP 22 target published by Berenberg on September 22, 2026.